VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SEER
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SEERSeer, Inc.
$2.22$122M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SEER logoSeer, Inc.(SEER)Earnings, Financials & Key Ratios

SEER•NASDAQ
$2.22
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryDiagnostics and Omics Tools
AboutSeer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.Show more
  • Revenue$16M+15.6%
  • EBITDA-$72M+23.0%
  • Net Income-$74M+15.0%
  • EPS (Diluted)-1.28+7.9%
  • Gross Margin11.8%-75.9%
  • EBITDA Margin-448.83%+33.4%
  • Operating Margin-486.7%+32.2%
  • Net Margin-456.6%+26.5%
  • ROE-25.08%-4.9%

SEER Price & Volume

Seer, Inc. (SEER) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Contraction Threatens Long-term Viability

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient liquidity runway

Key Thesis Takeaways

  • Seer, Inc.
  • faces a challenging fundamental outlook characterized by a 33.6% year-over-year revenue contraction in 2026Q1 and persistent operating losses that continue to erode the company's equity base.
  • While the company maintains a current ratio of 17.73, the rapid depletion of total assets from $436.3M in 2023Q4 to $272.1M in 2026Q1 suggests that current commercial adoption cycles are insufficient to sustain the existing research and development infrastructure.
  • Investors should monitor the company's ability to manage its $47.3M cash position against ongoing quarterly operating deficits, as the current trajectory indicates a high probability of future dilutive financing requirements.

Verdict Logic

the company's 33.6% revenue decline in 2026Q1 combined with a consistent pattern of negative free cash flow suggests that the current business model lacks the necessary scale to achieve profitability before exhausting its $47.3M cash reserve.

SEER Growth Metrics

Seer, Inc. (SEER) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years89.71%
3 Years3.15%
TTM-0.86%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM17.91%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM10.79%

Return on Capital

10 Years-21.53%
5 Years-21.72%
3 Years-24.69%
Last Year-24.84%

SEER Recent Earnings

Seer, Inc. (SEER) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 13, 2026
Metric
Actual
Est
EPS
$0.30-1.7%
$0.29
Rev
$3M-22.4%
$4M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.29+9.4%
$0.32
Rev
$4M-8.7%
$5M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.32+0.0%
$0.32
Rev
$4M-10.4%
$5M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.33+15.4%
$0.39
Rev
$4M+8.0%
$4M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 13, 2026
$0.30vs $0.29-1.7%
$3Mvs $4M-22.4%
Q1 2026Feb 26, 2026
$0.29vs $0.32+9.4%
$4Mvs $5M-8.7%
Q4 2025Nov 6, 2025
$0.32vs $0.32+0.0%
$4Mvs $5M-10.4%
Q3 2025Aug 6, 2025
$0.33vs $0.39+15.4%
$4Mvs $4M+8.0%
Based on last 12 quarters of dataView full earnings history →

Latest SEER News

Recent stock market news and headlines for Seer, Inc. (SEER)

GuruFocus·1 day ago
The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.'s Proposal to Acquire Seer, Inc.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7

Business Wire·1 day ago
The Radoff-JEC Group Responds to Chairman and CEO Omid Farokhzad, M.D.'s Proposal to Acquire Seer, Inc.

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement in response to Chairman and CEO Omid Farokhzad, M.D.'s July 1, 2026 proposal to acquire Seer: “For the first time, we agree with Dr. Farokhzad – Seer should not be a public company. Seer should b.

GlobeNewsWire·1 day ago
Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential

Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation

GlobeNewsWire·5 days ago
Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has received an unsolicited, non-binding proposal from Omid Farokhzad, M.D.

Business Wire·Jun 24, 2026
The Radoff-JEC Group Urges Seer, Inc. Stockholders to Vote for Boardroom Change Today

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement. Seer's Board of Directors (the “Board”) has destroyed value for stockholders while enriching Company insiders: The Company has posted a -97.0% share price decline since its December 2020 IPO.1 Seer ha.

Peers Comparison

Key metrics vs top competitors for Seer, Inc. (SEER)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SEER logoSEERSeer, Inc.Current
$2.22$122.06M-1.7315.57%-456.6%-25.08%—
QTRX logoQTRXQuanterix Corporation
$4.00$187.76M-1.592.38%-71.92%-35.17%—
CDNA logoCDNACareDx, Inc
$28.31$1.46B-70.7813.79%-1.98%-2.61%—
NAUT logoNAUTNautilus Biotechnology, Inc.
$1.69$214.76M-3.60——-35.04%—
ILMN logoILMNIllumina, Inc.
$191.76$29.13B35.19-0.78%19.43%32.84%—
PACB logoPACBPacific Biosciences of California, Inc.
$1.56$484.54M-0.863.89%-80.34%-488.45%—

Compare SEER vs Peers

Seer, Inc. (SEER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs QTRX

Most directly comparable listed peer for SEER.

Scale Benchmark

vs TMO

Larger-name benchmark to compare SEER against a more recognizable public peer.

Peer Set

Compare Top 5

vs QTRX, CDNA, NAUT, ILMN

SEER SEC Filings & Documents

Seer, Inc. (SEER) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 22, 2026·SEC

Material company update

May 13, 2026·SEC

Material company update

May 4, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 3, 2025·SEC

FY 2024

Mar 4, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 13, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when SEER posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SEER Frequently Asked Questions

Seer, Inc. (SEER) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Seer, Inc.'s revenue?

Seer, Inc. (SEER) reported $15.0M in revenue for fiscal year 2025.

How fast is Seer, Inc. growing?

Seer, Inc. (SEER) grew revenue by 15.6% over the past year. This is strong growth.

Is SEER profitable?

Seer, Inc. (SEER) reported a net loss of $70.5M for fiscal year 2025.

Dividend & Returns
What is SEER's return on equity?

Seer, Inc. (SEER) has a return on equity (ROE) of -25.1%. Negative ROE indicates the company is unprofitable.

What is Seer, Inc.'s free cash flow?

Seer, Inc. (SEER) had negative free cash flow of $49.9M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in SEER back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →